U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT07507526) titled 'A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer' on March 26.
Brief Summary: The goal of this clinical trial is to learn if the combination of disitamab vedotin, tunlametinib, and a PD-1 antibody works to treat HER2-overexpressing advanced gastric cancer in patients who have already received at least two lines of prior therapy. It will also learn about the safety of this combination therapy.
The main questions it aims to answer are:
What is the objective response rate (tumor shrinkage) in participants receiving this combination? What medical problems (side effects) do participants have whe...